Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

 

MDS/MPN
25:49

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Molecular Profiles-Guided Therapy in MDS: 5q-Syndrome Represents the Most Successful Therapy, Vidaza and Venetoclax May Be Valuable in Higher Risk Disease

FEATURING Eric Padron
  • 156 views
  • January 28, 2020
20:00

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

MDS/MPN Overlap Through Interactive Case Based Discussion: Overview of Disease, Molecular / Genomic Basis, and Treatment Options

FEATURING Andrew Kuykendall
  • 44 views
  • January 28, 2020
14:59

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

In Transplant-Eligible Patients With Higher-Risk MDS, Hypomethylating Agents Should Be Implemented Prior to Transplant

FEATURING Rami Komrokji
  • 181 views
  • January 28, 2020
18:24

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

In Transplant-Eligible Patients With Higher-Risk MDS, Hypomethylating Agents Implemented Prior to Transplant Do Not Alter Transplant Outcomes

FEATURING Asmita Mishra
  • 189 views
  • January 28, 2020
  • 1